You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.

This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.

Do you wish to leave this site?

Yes No

You are here Identifier : NCT03675308

A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

    Status Recruiting
    Related Conditions
    Psoriatic Arthritis

Enrollment Details

880 Worldwide Enrollment Goal


  • 1
  • 2
  • 3
  • 4
Study Type:  Interventional

This is a type III phase trial.

Protocol ID

Brief summary


The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in subjects with moderately to severely active psoriatic arthritis (PsA).

Participant Attributes :
  • Male and Female
  • Ages 18 Years and older

Canada: 7

Victoria, BC
Winnipeg, MB
Winnipeg, MB
Peterborough, ON
Waterloo, ON
Québec, QC
Saskatoon, SK
Would you like to know more about this trial?

Study Design

  • The general design that shows how the medical interventions will be assigned to the participants, e.g., whether all patients will receive the same drug, or if different groups receive two or more different treatments in a particular order.

    Intervention Model

    Parallel Assignment

  • The general design that describes the strategy for identifying and following up with participants during observational studies.


    Double (Participant/Investigator)

  • This is the single main reason for carrying out the clinical trial. Reasons can include: treatment, prevention, diagnostic advances, supportive care, screening, or health services research, among others.



    • Clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for PsA (CASPAR) at the Screening Visit.
    • Subject has active disease at Baseline
    • Diagnosis of active plaque psoriasis.
    • Subject has demonstrated an inadequate response or intolerance to conventional synthetic disease modifying anti-rheumatic drugs (csDMARD) therapy(ies).
    • Subject is considered by investigator, for any reason, to be an unsuitable candidate for the study.
    • Subject has a known hypersensitivity to risankizumab.
    • Subject has previous treatment with biologic agent.

More on this trial

Clinical Trials